News
OPK
1.480
+4.23%
0.060
U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Colgate-Palmolive, McKesson, Microsoft and Air Products & Chemicals among those. AIG, AIG and others have seen their target prices cut by some analysts.
Reuters · 3d ago
OPKO HEALTH INC <OPK.O>: JEFFERIES CUTS TARGET PRICE TO $2 FROM $2.5
Reuters · 3d ago
Weekly Report: what happened at OPK last week (0715-0719)?
Weekly Report · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Allstate, Quanta, First Industrial Realty
Wall Street's major indexes reversed early gains on Thursday. The Dow Jones Industrial Average was down 0.66% at 40,925.7. The top three S&P 500 percentage gainers were D.R. Horton, Barnes & Noble and First Industrial Realty.
Reuters · 07/18 17:56
BUZZ-U.S. STOCKS ON THE MOVE-Meta Platforms, Cintas, Toast
The Nasdaq and the S&P 500 bounced back on Thursday. An upbeat forecast from Taiwan Semiconductor Manufacturing lifted chip stocks after a sharp sell-off in the previous session. The Dow Jones Industrial Average was down 0.80% and the Nasdaq Composite was also down. Meta Platforms, Cintas and Toast are up.
Reuters · 07/18 16:49
Opko Health Stock Is Climbing: What's Going On?
Opko Health, Inc. Announced a $100 million share repurchase program. The company expects to fund the program from existing cash and cash equivalents and future cash flows. The new authorization represents 10.1% of the company's shares outstanding. Opko Health shares are trading higher Thursday.
Benzinga · 07/18 15:13
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
Shares of Cintas Corporation rose 5.3% to $758.25 after the company reported better-than-expected quarterly results. Dow Jones index gained 150 points on Thursday. Chuy’s Holdings, Inc. Shares gained 47.6% after company announced plans to acquire Chuy's.
Benzinga · 07/18 14:29
BUZZ-Opko Health climbs on stock buyback plan
Opko Health shares up 8.4% premarket to $1.54, highest since beginning of 2024. Biopharma and diagnostics firm plans to buy back stock. Co announces $100 mln share buyback program. Average rating among 6 analysts covering OPK is "strongbuy"
Reuters · 07/18 13:22
OPKO HEALTH ANNOUNCES $100 MILLION SHARE REPURCHASE PROGRAM
Reuters · 07/18 12:00
OPKO HEALTH INC - EXPECTS TO FUND REPURCHASE PROGRAM FROM EXISTING CASH AND CASH EQUIVALENTS, AND FUTURE CASH FLOWS
Reuters · 07/18 12:00
OPKO Health Is Maintained at Overweight by Piper Sandler
Dow Jones · 07/18 11:56
OPKO Health Price Target Cut to $3.00/Share From $5.00 by Piper Sandler
Dow Jones · 07/18 11:56
Piper Sandler Maintains Overweight on OPKO Health, Lowers Price Target to $3
Benzinga · 07/18 11:46
Opko Health (OPK) Gets a Buy from Piper Sandler
TipRanks · 07/18 10:39
OPKO HEALTH INC <OPK.O>: PIPER SANDLER CUTS TARGET PRICE TO $3 FROM $5
Reuters · 07/18 03:08
Why Opko Health Shares Are Up After-Hours
Opko Health enters into a $250 million non-dilutive note purchase agreement with HealthCare Royalty. The company's shares are trading higher after-hours Wednesday. Opko said the purchase agreement is secured by its profit share payments from Pfizer to treat pediatric growth hormone deficiency.
Benzinga · 07/17 21:31
Opko Health Secures $250M in Notes, Eyes Expansion
TipRanks · 07/17 20:48
OPKO Health and HealthCare Royalty enter $250M note purchase agreement
OPKO Health, Inc. Entered into a $250M note purchase agreement with HealthCare Royalty secured by profit share payments from Pfizer. The $250 million note bears interest at a rate of 4.0% per annum and has a maturity date of July 2044.
Seeking Alpha · 07/17 20:34
OPKO HEALTH INC: ALSO PERMITS OPKO TO MAINTAIN FULL BENEFIT OF $100 MLN OF REMAINING POTENTIAL MILESTONE PAYMENTS FROM PFIZER
Reuters · 07/17 20:14
OPKO HEALTH AND HEALTHCARE ROYALTY ENTER INTO $250 MILLION NOTE PURCHASE AGREEMENT SECURED BY NGENLA’S PROFIT SHARE PAYMENTS
Reuters · 07/17 20:14
More
Webull provides a variety of real-time OPK stock news. You can receive the latest news about Opko Health through multiple platforms. This information may help you make smarter investment decisions.
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.